Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with poor patient outcomes.
• Current treatments like chemotherapy and radiation are often ineffective against ATC.
• Novel molecularly targeted therapies are urgently needed for ATC.

Purpose of the Study:

• To investigate the efficacy of flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, against anaplastic thyroid cancer.
• To evaluate flavopiridol's effects on ATC cell proliferation, cell cycle progression, and migration.
• To assess flavopiridol's anti-tumor activity in an in vivo model of ATC.

Main Methods:

• Treatment of ATC cell lines (CAL62, KMH2, BHT-101) and a non-cancerous cell line (IMR-90) with flavopiridol across a concentration range.
• Assessment of cell viability using half-maximal inhibitory concentration (IC50).
• Analysis of cell cycle protein levels (CDK9, MCL1) and cell cycle arrest.
• In vitro colony formation and transwell migration assays.
• Evaluation of flavopiridol efficacy in a patient-derived ATC xenograft model.

Main Results:

• Flavopiridol demonstrated potent anti-cancer activity with sub-micromolar IC50 values in ATC cell lines, but not in normal cells.
• Treatment led to reduced levels of CDK9 and MCL1, and induced cell cycle arrest.
• Flavopiridol inhibited colony formation and cell migration in vitro.
• In vivo studies showed decreased tumor weight and volume in flavopiridol-treated xenografts.

Conclusions:

• Flavopiridol exhibits significant anti-cancer effects against anaplastic thyroid cancer in both in vitro and in vivo models.
• The drug effectively targets key cell cycle proteins and inhibits tumor growth.
• Flavopiridol warrants further clinical investigation as a potential therapeutic agent for ATC.